A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE).

Trial Profile

A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE).

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms X-PLORE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 25 Nov 2016 According to a Janssen media release, the company has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis. Data from three phase III studies (VOYAGE 1, VOYAGE 2, NAVIGATE) and a phase II study (X-PLORE8) supported the application.
    • 17 Nov 2016 According to a Janssen Biotech Inc. media release, the company has submitted Biologics License Application (BLA) to the US FDA seeking approval of guselkumab for the treatment of adults with moderate to severe plaque psoriasis. The application is based on data from phase III VOYAGE 1, VOYAGE 2, NAVIGATE trials and phase II X-PLORE trials.
    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top